liveBook · Manning

Kinase

As explained in Build AI Drug Discovery Pipelines

A protein kinase is an enzyme that transfers phosphate groups to proteins or other biological molecules.

A kinase is an enzyme that transfers a phosphate group from ATP to a substrate. This modification changes the substrate’s shape and function, switching signaling pathways on or off. section 8.1.1

Kinases are major small-molecule drug targets, particularly in cancer and inflammatory disease. Their broad influence over cell processes creates therapeutic opportunities but also makes selectivity difficult. section 8.1.1 section 1.4.1

Kinase inhibitor design must balance several practical requirements:

  • Bind the intended kinase with sufficient affinity. section 8.1.1
  • Avoid inhibiting other kinases, especially because many inhibitors target the conserved ATP-binding site. section 8.1.1 section 1.4.1
  • Use computational methods when testing specificity across the whole kinase family is too expensive for routine experimentation. section 8.1.1

Kinase inhibition in drug discovery

A small-molecule inhibitor can bind a kinase and interfere with enzyme function, preventing the normal conversion of substrate into product. The same strategy underlies kinase-focused oncology programs, while COX inhibition illustrates the broader use of enzyme inhibition for inflammation and its potential side effects. section 1.4.1

Figure 8.2 Map of human protein kinases, i.e., the Manning kinome tree, clustered based on sequence similarity into eight major groups [3].

The human kinome tree groups protein kinases by sequence similarity into eight major groups, making underexplored branches and approved-drug coverage easier to inspect. section 8.1.1

How Build AI Drug Discovery Pipelines covers it

How deep it goes
Explains phosphate transfer, signaling effects, inhibitor challenges, and computational motivation without detailing kinase structure or model implementation.
Examples
Uses the human kinome tree, oncology kinase inhibitors, and COX inhibition to illustrate families, targeting, and enzyme-inhibition tradeoffs.
What it assumes
Defines enzymes, substrates, ATP, inhibitors, ligands, and receptors before applying them to kinase drug discovery.
What you can do after
Evaluate kinase-focused computational models against affinity, selectivity, and model-credibility requirements.
How it connects
Connects kinases with ATP, enzymes, substrates, signaling pathways, protein-ligand interactions, kinase inhibitors, and drug discovery.

This explainer was generated by Manning's knowledge graph from the text of Build AI Drug Discovery Pipelines. The section links point to the parts of the book it draws on.